Shattuck Labs (STTK)
Market Price (8/22/2026): $7.545 | Market Cap: $979.2 MilSector: Health Care | Industry: Biotechnology
Shattuck Labs (STTK)
Market Price (8/22/2026): $7.545Market Cap: $979.2 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -21% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. | Trading close to highsDist 52W High is -4.9% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -56 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -5579% Expensive valuation multiplesP/SPrice/Sales ratio is 977x Stock price has recently run up significantly12M Rtn12 month market price return is 742% Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -67% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 853% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -4103%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -4103% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -9.8% Key risksSTTK key risks include [1] the unpredictable outcome of its clinical trials and subsequent regulatory approvals and [2] future liquidity needs, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -21% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. |
| Trading close to highsDist 52W High is -4.9% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -56 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -5579% |
| Expensive valuation multiplesP/SPrice/Sales ratio is 977x |
| Stock price has recently run up significantly12M Rtn12 month market price return is 742% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -67% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 853% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -4103%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -4103% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -9.8% |
| Key risksSTTK key risks include [1] the unpredictable outcome of its clinical trials and subsequent regulatory approvals and [2] future liquidity needs, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Shattuck Labs (STTK) stock has gained about 5% since 4/30/2026 because of the following key factors:
1. Shattuck Labs significantly bolstered its financial position through successful capital raises, extending its cash runway into 2029. The company completed an underwritten public offering, generating approximately $86.2 million in aggregate gross proceeds. Additionally, the exercise of approximately 50.6 million common stock warrants resulted in an estimated $54.9 million in gross proceeds. These efforts collectively increased cash, cash equivalents, and short-term investments to $208.3 million by the end of fiscal Q2 2026 (June 30, 2026), compared to $50.5 million a year earlier. This strengthened balance sheet is crucial for a clinical-stage biotechnology company to fund ongoing operations and pipeline development.
2. Positive Phase 1 clinical data for its lead asset, SL-325, and its subsequent advancement to a Phase 2b trial provided a significant catalyst. On June 8, 2026, Shattuck Labs announced favorable Phase 1 results for SL-325, a DR3-blocking antibody, demonstrating a strong safety profile, a low 3.7% incidence of antidrug antibodies, and durable TL1A/DR3 blockade lasting over three months at doses of 1 mg/kg or higher. Building on these results, the company is on track to initiate the RECEPTIVE-CD1 Phase 2b trial in fiscal Q3 2026, targeting Crohn's disease patients. The trial design was expanded to evaluate three dose levels in approximately 232 patients, compared to a previous two-dose, 174-patient framework.
Show more
Shattuck Labs (STTK) stock has gained about 5% since 4/30/2026 because of the following key factors:
1. Shattuck Labs significantly bolstered its financial position through successful capital raises, extending its cash runway into 2029. The company completed an underwritten public offering, generating approximately $86.2 million in aggregate gross proceeds. Additionally, the exercise of approximately 50.6 million common stock warrants resulted in an estimated $54.9 million in gross proceeds. These efforts collectively increased cash, cash equivalents, and short-term investments to $208.3 million by the end of fiscal Q2 2026 (June 30, 2026), compared to $50.5 million a year earlier. This strengthened balance sheet is crucial for a clinical-stage biotechnology company to fund ongoing operations and pipeline development.
2. Positive Phase 1 clinical data for its lead asset, SL-325, and its subsequent advancement to a Phase 2b trial provided a significant catalyst. On June 8, 2026, Shattuck Labs announced favorable Phase 1 results for SL-325, a DR3-blocking antibody, demonstrating a strong safety profile, a low 3.7% incidence of antidrug antibodies, and durable TL1A/DR3 blockade lasting over three months at doses of 1 mg/kg or higher. Building on these results, the company is on track to initiate the RECEPTIVE-CD1 Phase 2b trial in fiscal Q3 2026, targeting Crohn's disease patients. The trial design was expanded to evaluate three dose levels in approximately 232 patients, compared to a previous two-dose, 174-patient framework.
3. Shattuck Labs reported better-than-expected financial results for fiscal Q1 2026, exceeding analyst earnings estimates. On May 7, 2026, the company announced an earnings per share (EPS) of -$0.13 for fiscal Q1 2026, surpassing the consensus analyst estimate of -$0.14 by $0.01. While still reporting a net loss, this beat on earnings per share contributed positively to investor sentiment.
4. Continued positive analyst coverage and high price targets have supported the stock's upward trend. As of August 7, 2026, seven analysts provided a consensus "Buy" rating for STTK, with a collective price target of $15. Throughout the period, firms like H.C. Wainwright (maintaining a "Buy" with a $14 target as of August 12, 2026), JPMorgan (reiterating "Overweight" with a $10 target), Leerink Partners (initiating "Outperform" with a $16 objective in July 2026), and Wedbush (raising its target to $11 in May 2026) maintained favorable outlooks, indicating confidence in the company's pipeline and strategic direction.
Show less
Stock Movement Drivers
Fundamental Drivers
The 5.3% change in STTK stock from 4/30/2026 to 8/21/2026 was primarily driven by a 31.4% change in the company's P/S Multiple.| (LTM values as of) | 4302026 | 8212026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.15 | 7.53 | 5.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 1 | 0.0% |
| P/S Multiple | 743.8 | 977.2 | 31.4% |
| Shares Outstanding (Mil) | 104 | 130 | -19.8% |
| Cumulative Contribution | 5.3% |
Market Drivers
4/30/2026 to 8/21/2026| Return | Correlation | |
|---|---|---|
| STTK | 5.3% | |
| Market (SPY) | 6.5% | 19.5% |
| Sector (XLV) | 19.6% | 17.5% |
Fundamental Drivers
The 94.6% change in STTK stock from 1/31/2026 to 8/21/2026 was primarily driven by a 249.8% change in the company's P/S Multiple.| (LTM values as of) | 1312026 | 8212026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.87 | 7.53 | 94.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 1 | 0.0% |
| P/S Multiple | 279.4 | 977.2 | 249.8% |
| Shares Outstanding (Mil) | 72 | 130 | -44.4% |
| Cumulative Contribution | 94.6% |
Market Drivers
1/31/2026 to 8/21/2026| Return | Correlation | |
|---|---|---|
| STTK | 94.6% | |
| Market (SPY) | 11.0% | 17.3% |
| Sector (XLV) | 13.3% | 10.6% |
Fundamental Drivers
The 888.7% change in STTK stock from 7/31/2025 to 8/21/2026 was primarily driven by a 11496.3% change in the company's P/S Multiple.| (LTM values as of) | 7312025 | 8212026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.76 | 7.53 | 888.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 5 | 1 | -78.3% |
| P/S Multiple | 8.4 | 977.2 | 11496.3% |
| Shares Outstanding (Mil) | 51 | 130 | -60.7% |
| Cumulative Contribution | 888.7% |
Market Drivers
7/31/2025 to 8/21/2026| Return | Correlation | |
|---|---|---|
| STTK | 888.7% | |
| Market (SPY) | 22.2% | 19.0% |
| Sector (XLV) | 35.6% | 13.9% |
Fundamental Drivers
The 195.3% change in STTK stock from 7/31/2023 to 8/21/2026 was primarily driven by a 540.2% change in the company's P/S Multiple.| (LTM values as of) | 7312023 | 8212026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.55 | 7.53 | 195.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 1 | 41.0% |
| P/S Multiple | 152.6 | 977.2 | 540.2% |
| Shares Outstanding (Mil) | 42 | 130 | -67.3% |
| Cumulative Contribution | 195.3% |
Market Drivers
7/31/2023 to 8/21/2026| Return | Correlation | |
|---|---|---|
| STTK | 195.3% | |
| Market (SPY) | 73.2% | 19.2% |
| Sector (XLV) | 36.3% | 18.3% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| STTK Return | -84% | -73% | 210% | -83% | 202% | 99% | -86% |
| Peers Return | 36% | 21% | 2% | 8% | 26% | 25% | 185% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 12% | 103% |
Monthly Win Rates [3] | |||||||
| STTK Win Rate | 25% | 17% | 58% | 42% | 58% | 88% | |
| Peers Win Rate | 62% | 62% | 43% | 47% | 60% | 65% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| STTK Max Drawdown | -84% | -78% | -71% | -91% | -62% | -51% | |
| Peers Max Drawdown | -16% | -18% | -23% | -21% | -22% | -15% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: MRK, ABBV, PFE, LLY, JNJ.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 8/21/2026 (YTD)
How Low Can It Go
| Event | STTK | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -41.8% | -18.8% |
| % Gain to Breakeven | 71.9% | 23.1% |
| Time to Breakeven | 3 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -18.9% | -7.8% |
| % Gain to Breakeven | 23.3% | 8.5% |
| Time to Breakeven | 29 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -47.5% | -9.5% |
| % Gain to Breakeven | 90.5% | 10.5% |
| Time to Breakeven | 71 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -44.4% | -6.7% |
| % Gain to Breakeven | 79.8% | 7.1% |
| Time to Breakeven | 210 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -70.9% | -24.5% |
| % Gain to Breakeven | 243.2% | 32.4% |
| Time to Breakeven | 438 days | 427 days |
In The Past
Shattuck Labs's stock fell -41.8% during the 2025 US Tariff Shock. Such a loss loss requires a 71.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | STTK | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -41.8% | -18.8% |
| % Gain to Breakeven | 71.9% | 23.1% |
| Time to Breakeven | 3 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -47.5% | -9.5% |
| % Gain to Breakeven | 90.5% | 10.5% |
| Time to Breakeven | 71 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -44.4% | -6.7% |
| % Gain to Breakeven | 79.8% | 7.1% |
| Time to Breakeven | 210 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -70.9% | -24.5% |
| % Gain to Breakeven | 243.2% | 32.4% |
| Time to Breakeven | 438 days | 427 days |
In The Past
Shattuck Labs's stock fell -41.8% during the 2025 US Tariff Shock. Such a loss loss requires a 71.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Shattuck Labs (STTK)
Shattuck Labs, Inc. (STTK) is a clinical-stage biotechnology company dedicated to developing novel therapeutic agents for severe medical conditions. Headquartered in Austin, Texas, the company's core focus is on creating treatments for both cancer and autoimmune diseases, currently advancing its product candidates through early-stage human clinical trials.
The company's lead product candidates are designed to address various forms of cancer. SL-172154 is currently in Phase 1 clinical trials for ovarian, fallopian tube, and peritoneal cancers. Concurrently, Shattuck Labs is developing SL-279252, also in Phase 1 trials, aimed at treating patients with advanced solid tumors and lymphoma. Ultimately, Shattuck Labs seeks to serve patients suffering from these challenging diseases by introducing innovative treatment solutions into the biotechnology market.
AI Analysis | Feedback
Here are a few analogies for Shattuck Labs:
A startup Amgen for cancer and autoimmune drug discovery.
Like a small, independent R&D lab for Pfizer or Merck, but focused on experimental drugs for cancer and autoimmune diseases.
AI Analysis | Feedback
- SL-172154: A therapeutic product candidate in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.
- SL-279252: A therapeutic product candidate in Phase 1 clinical trial for patients with advanced solid tumors and lymphoma.
AI Analysis | Feedback
Shattuck Labs, Inc. (STTK) is a clinical-stage biotechnology company focused on developing therapeutics for cancer and autoimmune diseases. As described, their lead product candidates are currently in Phase 1 clinical trials. This means the company is in the research and development phase and has not yet commercialized any products or services.
Therefore, Shattuck Labs does not have major customers in the traditional sense of companies or individuals purchasing their products or services.
AI Analysis | Feedback
AI Analysis | Feedback
Taylor H. Schreiber, MD, PhD Chief Executive Officer, Co-founder, and Director
Dr. Schreiber co-founded Shattuck Labs in 2016 and served as Chief Scientific Officer before his appointment as CEO in January 2020. Prior to Shattuck, he served as Chief Scientific Officer of Heat Biologics, Inc., where he co-invented significant elements of their ImPACT and ComPACT technology platforms. He also co-invented TNFRSF25 agonist technology developed by Pelican Therapeutics, Inc., where he served as Chairman of the Scientific Advisory Board. Pelican Therapeutics was sold in 2017.
Andrew R. Neill Chief Financial Officer
Mr. Neill has served as Chief Financial Officer of Shattuck Labs since March 2021, having joined the company in 2017. He previously served as Vice President of Finance and Corporate Strategy, and Vice President of Corporate Development and Strategy. Prior to joining Shattuck, Mr. Neill was the co-founder of Lumos Pharma, a biopharmaceutical company focused on developing therapeutics for genetic rare diseases. He played a key role in Shattuck's Series B and B-1 financings and initial public offering.
Lini Pandite, MD, MBA Chief Medical Officer
Dr. Pandite joined Shattuck Labs in July 2017 as Chief Medical Officer. She brings over 25 years of academic, medical, and pharmaceutical experience with broad expertise in oncology drug development, spanning from early-to-late phase development through registration and commercialization.
Suresh de Silva, PhD Chief Scientific Officer
Dr. de Silva has served as Chief Scientific Officer since January 2023. He joined Shattuck in 2017 and is one of the scientific co-inventors of the ARC technology platform. He previously served as Vice President of Product Development and Executive Director of Research and Development. Prior to Shattuck, he was the Director of Research and Development at Heat Biologics, Inc., where he co-developed the ComPact cell-based vaccine platform.
Casi DeYoung Chief Business Officer
Ms. DeYoung has served as Chief Business Officer since December 2019. From June 2018 to December 2019, she served as Vice President and Chief Operating Officer for ImmuneSensor Therapeutics, an immunotherapy-focused biotechnology company, where she was responsible for corporate strategy, start-up operations, intellectual property, oversight of the company's first IND filing, and the initiation of a first-in-human Phase I clinical trial.
AI Analysis | Feedback
The key risks for Shattuck Labs (STTK), a clinical-stage biotechnology company, primarily revolve around the inherent uncertainties of drug development and commercialization in the highly regulated and competitive biotechnology sector.
-
Clinical Trial Failure: Shattuck Labs' valuation and future prospects are heavily dependent on the successful outcome of its ongoing clinical trials, particularly for its lead product candidate, SL-325. There is no guarantee that preliminary data for SL-325, currently in Phase 1 for inflammatory bowel diseases (IBD), will be positive or viewed favorably by the market. The company has previously discontinued its SL-172154 oncology program due to "modest improvement" in overall survival, highlighting the tangible risk and impact of clinical trial failures, which can lead to significant financial losses and strategic shifts. Biotechnology development is characterized by high attrition rates and substantial development costs, making clinical success a paramount risk.
-
Regulatory Approval Risk: As with all biotechnology companies, Shattuck Labs faces significant inherent risks associated with obtaining regulatory approvals for its drug candidates. The U.S. Food and Drug Administration (FDA) approval process is complex, lengthy, and never guaranteed, even with positive clinical data. Failure to comply with stringent regulatory requirements can result in severe penalties, delaying or preventing market access for potential therapies.
-
Lack of Profitability and Dependence on Future Funding: Shattuck Labs is currently a clinical-stage company with no product revenue, operating with significant net losses and negative operating margins. While the company has extended its cash runway, anticipating sufficient capital into 2029, this projection is contingent upon the full exercise of outstanding common stock warrants. The biotechnology industry often faces challenges in raising capital, particularly in an uncertain economic landscape, making sustained profitability and access to future funding critical risks.
AI Analysis | Feedback
AI Analysis | Feedback
Shattuck Labs (STTK) was developing therapeutics for several cancer indications. While their lead product candidates, SL-172154 and SL-279252, were initially aimed at these markets, Shattuck Labs has since discontinued their clinical development for these specific oncology programs.
Here are the addressable market sizes for the indications that Shattuck Labs' main products were initially targeting:
SL-172154 (Discontinued Oncology Program)
SL-172154 was in Phase 1 clinical trials for the treatment of ovarian, fallopian tube, and peritoneal cancers. However, Shattuck Labs discontinued the SL-172154 clinical program in October 2024 due to modest improvements in median overall survival compared to benchmarks, and shifted focus to other programs.
- Ovarian Cancer: The global ovarian cancer market size was valued at approximately USD 2.5 billion in 2025 and is projected to reach USD 5.8 billion by 2034, with a Compound Annual Growth Rate (CAGR) of 9.21% from 2026 to 2034. North America is a leading region in this market.
- Fallopian Tube Cancer: The global fallopian tube cancer treatment market size was valued at USD 1.80 billion in 2025 and is expected to reach USD 3.35 billion by 2033, growing at a CAGR of 8.10%. North America held the largest revenue share in this market in 2025. The global fallopian tube cancer therapeutics market size was also calculated at USD 1.93 billion in 2025 and is predicted to increase to approximately USD 5.41 billion by 2035, expanding at a CAGR of 10.86% from 2026 to 2035.
- Peritoneal Cancer: Market sizes for primary peritoneal cancer are often integrated with those of ovarian and fallopian tube cancers due to their clinical similarities and shared treatment approaches.
SL-279252 (Discontinued Oncology Program)
SL-279252 was in Phase 1 clinical trials for advanced solid tumors and lymphoma. Shattuck Labs discontinued clinical development of SL-279252 in February 2023 because it did not observe an overall response rate necessary to justify continued development.
- Advanced Solid Tumors: The global solid tumors market size was valued at USD 362.21 billion in 2024 and is projected to reach USD 1557.42 billion by 2032, with a CAGR of 20.00% during the forecast period of 2025 to 2032. North America dominates the solid tumors market. Another source indicates the global solid tumor therapeutics market size reached USD 223.65 billion in 2026 and is forecast to reach USD 326.82 billion by 2031.
- Lymphoma: The global lymphoma treatment market size was valued at USD 8.3 billion in 2024 and is expected to reach USD 18.3 billion by 2034, growing at a CAGR of 8.4% from 2025 to 2034. The U.S. lymphoma treatment market was valued at USD 2.9 billion in 2023 and is projected to reach USD 6.8 billion by 2034. North America held a dominant share of approximately 49% in the global lymphoma treatment market in 2024.
AI Analysis | Feedback
Here are the expected drivers of future revenue growth for Shattuck Labs (STTK) over the next 2-3 years:
- Successful Clinical Development and Regulatory Progress of SL-325: Shattuck Labs has shifted its primary focus to SL-325, a Death Receptor 3 (DR3) antagonist antibody, for the treatment of inflammatory bowel disease (IBD) and other inflammatory conditions. The company anticipated filing an Investigational New Drug (IND) application for SL-325 and initiating a Phase 1 clinical trial in the third quarter of 2025. Positive data from this ongoing Phase 1 trial and subsequent clinical development stages would be a key driver for future revenue, potentially leading to regulatory approvals and market entry.
- Strategic Partnerships and Licensing Agreements for SL-325: As a clinical-stage biotechnology company, a significant driver of future revenue growth could come from securing strategic collaborations or licensing agreements for SL-325. Successful early-stage clinical data for SL-325 could attract larger pharmaceutical partners, potentially resulting in upfront payments, milestone payments, and future royalties, which could contribute to revenue within the specified timeframe.
- Expansion of the DR3 Blocking Antibody Pipeline: Beyond SL-325, Shattuck Labs is also working on nominating additional lead DR3 bispecific development candidates. The successful advancement and diversification of its DR3 blocking antibody pipeline could create multiple future product opportunities and revenue streams in the long term, building upon the initial development of SL-325.
AI Analysis | Feedback
Share Repurchases
No information available regarding share repurchases or authorized future share repurchases over the last 3-5 years.
Share Issuance
- Shattuck Labs sold shares of its common stock under an at-the-market offering facility, generating aggregate gross proceeds of $21.4 million in the first quarter of 2026.
- The company's number of shares outstanding increased by 37.09% in one year.
- As of February 28, 2026, cash, cash equivalents, and short-term investments totaled approximately $94.5 million, which included the $21.4 million in gross proceeds from at-the-market stock sales.
Inbound Investments
- As a result of at-the-market stock sales in the first quarter of 2026, accounts advised by T. Rowe Price Investment Management, Inc. reported beneficial ownership exceeding 10% of Shattuck Labs' outstanding common stock.
Capital Expenditures
- Shattuck Labs' capital expenditures in the last 12 months were -$71,000.
- The company reported $0 in capital expenditures in the fourth quarter of 2025.
Peer Outperformance in Biotechnology
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 7 | 5.7% | 83.3% | 124.2% | CAH 398% · MCK 340% · COR 181% |
| Health Care Services | 20 | 22.9% | 44.2% | 10.6% | HIMS 375% · RDNT 151% · DGX 77% |
| Managed Health Care | 8 | 32.1% | -3.6% | 0.1% | OSCR 136% · HQY 67% · ELV 14% |
| Health Care Facilities | 24 | 9.8% | -1.1% | -16.4% | THC 287% · NHC 260% · ENSG 122% |
| Health Care Equipment | 51 | -1.7% | -4.9% | -18.4% | POCI 11300% · UFPT 376% · GKOS 278% |
| Health Care Supplies | 12 | 39.5% | -12.8% | -25.9% | LNTH 300% · HAE 82% · MMSI 31% |
| Pharmaceuticals | 63 | 7.3% | 5.3% | -32.8% | LQDA 2549% · ETON 1339% · INDV 1291% |
| Life Sciences Tools & Services | 108 | -1.9% | -30.8% | -69.8% | SNWV 1782% · MEDP 248% · ELMD 245% |
| Health Care Technology | 21 | -17.0% | -54.1% | -71.5% | SPOK 114% · HSTM -2% · VEEV -23% |
| Biotechnology ← | 365 | 10.8% | -25.4% | -77.6% | BRTX 107550% · CELZ 1771% · DNTH 1612% |
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 208.75 |
| Mkt Cap | 422.8 |
| Rev LTM | 65,478 |
| Op Inc LTM | 19,434 |
| FCF LTM | 14,812 |
| FCF 3Y Avg | 12,028 |
| CFO LTM | 19,737 |
| CFO 3Y Avg | 16,454 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.3% |
| Rev Chg 3Y Avg | 5.4% |
| Rev Chg Q | 6.6% |
| QoQ Delta Rev Chg LTM | 1.4% |
| Op Inc Chg LTM | 17.8% |
| Op Inc Chg 3Y Avg | 26.3% |
| Op Mgn LTM | 26.8% |
| Op Mgn 3Y Avg | 24.0% |
| QoQ Delta Op Mgn LTM | -0.2% |
| CFO/Rev LTM | 29.1% |
| CFO/Rev 3Y Avg | 24.9% |
| FCF/Rev LTM | 20.0% |
| FCF/Rev 3Y Avg | 18.2% |
Price Behavior
| Market Price | $7.53 | |
| Market Cap ($ Bil) | 0.8 | |
| First Trading Date | 10/09/2020 | |
| Distance from 52W High | -4.9% | |
| 50 Days | 200 Days | |
| DMA Price | $6.56 | $5.19 |
| DMA Trend | up | up |
| Distance from DMA | 14.8% | 45.2% |
| 3M | 1YR | |
| Volatility | 94.2% | 93.9% |
| Downside Capture | -23.40 | 48.83 |
| Upside Capture | 76.93 | 283.24 |
| Correlation (SPY) | 14.1% | 23.6% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.20 | 0.53 | 0.96 | 0.82 | 1.41 | 1.71 |
| Up Beta | 5.01 | 3.91 | 3.81 | 2.38 | 1.68 | 1.71 |
| Down Beta | -3.02 | 1.21 | 0.24 | -0.63 | 1.56 | 2.27 |
| Up Capture | 164% | -19% | 28% | 137% | 579% | 375% |
| Bmk +ve Days | 11 | 22 | 35 | 67 | 138 | 427 |
| Stock +ve Days | 11 | 23 | 30 | 64 | 129 | 360 |
| Down Capture | 132% | -152% | 45% | 16% | -5% | 107% |
| Bmk -ve Days | 11 | 21 | 28 | 59 | 114 | 326 |
| Stock -ve Days | 11 | 20 | 33 | 60 | 118 | 369 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with STTK | |
|---|---|---|---|---|
| STTK | 651.5% | 94.5% | 2.54 | - |
| Sector ETF (XLV) | 28.8% | 16.0% | 1.39 | 12.3% |
| Equity (SPY) | 21.1% | 12.9% | 1.22 | 23.3% |
| Gold (GLD) | 37.5% | 28.8% | 1.10 | 9.4% |
| Commodities (DBC) | 43.2% | 20.2% | 1.66 | -0.9% |
| Real Estate (VNQ) | 12.9% | 13.8% | 0.64 | 15.4% |
| Bitcoin (BTCUSD) | -35.4% | 43.5% | -0.88 | 14.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with STTK | |
|---|---|---|---|---|
| STTK | -16.6% | 118.2% | 0.33 | - |
| Sector ETF (XLV) | 7.1% | 15.1% | 0.28 | 17.6% |
| Equity (SPY) | 12.9% | 17.2% | 0.57 | 20.0% |
| Gold (GLD) | 20.6% | 18.6% | 0.90 | 2.9% |
| Commodities (DBC) | 10.4% | 19.6% | 0.41 | -0.0% |
| Real Estate (VNQ) | 2.3% | 18.9% | 0.02 | 18.6% |
| Bitcoin (BTCUSD) | 9.1% | 52.7% | 0.36 | 12.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with STTK | |
|---|---|---|---|---|
| STTK | -8.2% | 113.6% | 0.34 | - |
| Sector ETF (XLV) | 10.7% | 16.7% | 0.52 | 15.3% |
| Equity (SPY) | 15.2% | 17.9% | 0.72 | 18.6% |
| Gold (GLD) | 12.7% | 16.2% | 0.64 | 2.3% |
| Commodities (DBC) | 8.0% | 18.0% | 0.36 | 0.6% |
| Real Estate (VNQ) | 5.0% | 20.7% | 0.20 | 17.0% |
| Bitcoin (BTCUSD) | 62.2% | 66.1% | 1.02 | 11.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 8/11/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/5/2026 | 7.8% | 24.3% | 35.7% |
| 5/1/2025 | -7.8% | -13.0% | -3.2% |
| 11/14/2024 | 12.3% | -9.0% | -6.6% |
| 11/9/2023 | -23.2% | -8.9% | 0.0% |
| 8/10/2023 | -2.3% | -5.9% | -1.4% |
| 5/9/2023 | -2.1% | -7.0% | 2.8% |
| 2/23/2023 | 0.4% | -9.5% | -33.3% |
| 11/8/2022 | -5.9% | 1.8% | 6.8% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 8 | 4 | 7 |
| # Negative | 7 | 11 | 8 |
| Median Positive | 5.9% | 11.5% | 6.8% |
| Median Negative | -5.9% | -7.0% | -9.0% |
| Max Positive | 12.3% | 24.3% | 35.7% |
| Max Negative | -28.6% | -34.5% | -50.6% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/5/2026 | 7.8% | 24.3% | 35.7% |
| 5/1/2025 | -7.8% | -13.0% | -3.2% |
| 11/14/2024 | 12.3% | -9.0% | -6.6% |
| 11/9/2023 | -23.2% | -8.9% | 0.0% |
| 8/10/2023 | -2.3% | -5.9% | -1.4% |
| 5/9/2023 | -2.1% | -7.0% | 2.8% |
| 2/23/2023 | 0.4% | -9.5% | -33.3% |
| 11/8/2022 | -5.9% | 1.8% | 6.8% |
| 8/11/2022 | -4.4% | -6.7% | -17.3% |
| 5/12/2022 | 8.3% | -5.8% | 27.3% |
| 3/15/2022 | 3.3% | 12.8% | -11.4% |
| 11/9/2021 | -28.6% | -34.5% | -50.6% |
| 8/11/2021 | 2.6% | -3.1% | -0.0% |
| 5/10/2021 | 4.4% | -1.8% | 5.2% |
| 11/13/2020 | 7.5% | 10.1% | 19.9% |
| SUMMARY STATS | |||
| # Positive | 8 | 4 | 7 |
| # Negative | 7 | 11 | 8 |
| Median Positive | 5.9% | 11.5% | 6.8% |
| Median Negative | -5.9% | -7.0% | -9.0% |
| Max Positive | 12.3% | 24.3% | 35.7% |
| Max Negative | -28.6% | -34.5% | -50.6% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/11/2026 | 10-Q |
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 03/05/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/01/2025 | 10-Q |
| 12/31/2024 | 03/27/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/01/2024 | 10-Q |
| 03/31/2024 | 05/02/2024 | 10-Q |
| 12/31/2023 | 02/29/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 02/23/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/11/2026 | 10-Q |
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 03/05/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/01/2025 | 10-Q |
| 12/31/2024 | 03/27/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/01/2024 | 10-Q |
| 03/31/2024 | 05/02/2024 | 10-Q |
| 12/31/2023 | 02/29/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 02/23/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
| 03/31/2022 | 05/12/2022 | 10-Q |
| 12/31/2021 | 03/15/2022 | 10-K |
| 09/30/2021 | 11/09/2021 | 10-Q |
| 06/30/2021 | 08/12/2021 | 10-Q |
| 03/31/2021 | 05/10/2021 | 10-Q |
| 12/31/2020 | 03/16/2021 | 10-K |
| 09/30/2020 | 11/13/2020 | 10-Q |
| 06/30/2020 | 10/13/2020 | 424B4 |
Recent Forward Guidance
Updated 7/27/2026Latest: Q4 2025 Earnings Reported 3/5/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2029 Cash Runway | |||||||
Insider Activity
Updated 7/7/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Shukla, Abhinav A | Chief Technical Officer | Direct | Sell | 7072026 | 7.01 | 410 | 2,874 | 605,524 | Form |
| 2 | Shukla, Abhinav A | Chief Technical Officer | Direct | Sell | 7022026 | 7.07 | 100 | 707 | 610,707 | Form |
| 3 | Shukla, Abhinav A | Chief Technical Officer | Direct | Sell | 7022026 | 7.08 | 23,365 | 165,424 | 611,570 | Form |
| 4 | Pandite, Arundathy N | Chief Medical Officer | Direct | Sell | 7022026 | 7.01 | 30,000 | 210,300 | 954,895 | Form |
| 5 | Siegall, Clay B | Direct | Buy | 6112026 | 4.00 | 62,500 | 250,000 | 1,274,432 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Shukla, Abhinav A | Chief Technical Officer | Direct | Sell | 7072026 | 7.01 | 410 | 2,874 | 605,524 | Form |
| 2 | Shukla, Abhinav A | Chief Technical Officer | Direct | Sell | 7022026 | 7.07 | 100 | 707 | 610,707 | Form |
| 3 | Shukla, Abhinav A | Chief Technical Officer | Direct | Sell | 7022026 | 7.08 | 23,365 | 165,424 | 611,570 | Form |
| 4 | Pandite, Arundathy N | Chief Medical Officer | Direct | Sell | 7022026 | 7.01 | 30,000 | 210,300 | 954,895 | Form |
| 5 | Siegall, Clay B | Direct | Buy | 6112026 | 4.00 | 62,500 | 250,000 | 1,274,432 | Form | |
| 6 | Shukla, Abhinav A | Chief Technical Officer | Direct | Sell | 5142026 | 7.01 | 2,032 | 14,244 | 569,619 | Form |
| 7 | Pandite, Arundathy N | Chief Medical Officer | Direct | Sell | 5142026 | 6.61 | 30,000 | 198,300 | 1,098,708 | Form |
| 8 | Orbimed, Advisors Llc | See Footnote | Buy | 9022025 | 0.87 | 6,306,127 | 5,471,826 | 4,559,855 | Form | |
| 9 | Ashiya, Mona | See Footnote | Buy | 9022025 | 0.87 | 6,306,127 | 5,471,826 | 4,559,855 | Form |
Investor Activity (13F)
Updated Aug 22, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager |
|---|
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.